剂量异质性对微束放射治疗抗肿瘤反应的重要意义
该研究在大鼠胶质母细胞瘤原位模型中采用多种质子微束放射治疗(pMBRT)配置,探讨峰值剂量、谷值剂量、峰谷剂量比(PVDR)等剂量学参数对生存和免疫应答的影响,并用X射线MBRT进一步评估峰值剂量与剂量异质性的作用。结果提示维持最低谷值剂量并提高由峰值剂量驱动的剂量异质性可改善生存,较高的PVDR促进免疫抑制性更低的微环境。
要点
- 维持最低谷值剂量并提高剂量异质性可改善多种pMBRT方案下的大鼠生存。
- 较高的PVDR促进免疫抑制性更低的肿瘤微环境。
- 平均剂量未影响免疫浸润,肿瘤清除与免疫浸润均与更高的剂量异质性相关。
核心结论
- 结果提示肿瘤清除和免疫浸润均与更高的剂量异质性相关,更高的剂量异质性通过优化峰值剂量并维持最低谷值剂量实现。
- 这些参数有助于直接清除肿瘤并减少免疫抑制,与传统质子治疗均匀剂量分布下更具免疫抑制性的肿瘤环境不同。
研究设计与样本
- 研究采用大鼠胶质母细胞瘤原位模型,接受多种pMBRT配置。
- 研究评估了不同剂量学参数对生存及免疫应答等关键机制的影响,免疫应答于照射后7天通过免疫组化和流式细胞术评估。
- 研究还评估了X射线MBRT的效果,以进一步阐明峰值剂量和剂量异质性的影响。
主要发现
- 多种pMBRT方案通过维持最低谷值剂量以及由峰值剂量驱动的更高剂量异质性改善了生存。
- 平均剂量未影响免疫浸润,而较高的PVDR促进了免疫抑制性更低的微环境。
- 肿瘤清除和免疫浸润均与更高的剂量异质性相关。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: Proton Minibeam Radiation Therapy (pMBRT) is an unconventional radiation technique based on a strong modulation of the dose deposition. Due to its specific pattern, pMBRT involves several dosimetry (peak and valley doses, peak-to-valley dose ratio (PVDR)) and geometrical parameters (beam width, spacing) that can influence the biological response. This study aims at contributing to the efforts to deepen the comprehension of how the various parameters relate to central biological mechanisms, particularly anti-tumor immunity, and how these correlations affect treatment outcomes with the goal to fully unleash the potential of pMBRT. We also evaluated the effects of X-ray MBRT to further elucidate the influence of peak dose and dose heterogeneity. METHODS AND MATERIALS: An orthotopic rat model of glioblastoma underwent several pMBRT configurations. The impact of different dosimetric parameters on survival and on the modulation of crucial mechanisms for pMBRT, such as immune response, was investigated. The latter was assessed by immunohistochemistry and flow cytometry at 7 days post-irradiation. RESULTS: Survival was improved across the various pMBRT regimens via maintaining a minimum valley dose as well as a higher dose heterogeneity, which is driven by peak dose. While the mean dose did not impact immune infiltration, a higher PVDR promoted a less immunosuppressive microenvironment. CONCLUSIONS: Our results suggest that both tumor eradication, and immune infiltration are associated with higher dose heterogeneity. Higher dose heterogeneity was achieved by optimizing the peak dose, as well as maintaining a minimum valley dose. These parameters contributed to direct tumor eradication as well as reduction of immunosuppression, which is a departure from the more immunosuppressive tumor environment found in conventional proton therapy that delivers uniform dose distributions.
引用
- Potiron S, Iturri L, Juchaux M, et al. The significance of dose heterogeneity on the anti-tumor response of minibeam radiation therapy. Radiother Oncol. 2024. PMID: 39393469. doi:10.1016/j.radonc.2024.110577
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。